Lealing Biopharma develops TCR-T cell therapies and TCR dual-antibody drugs targeting intracellular mechanisms to treat solid tumors and viral diseases. Their proprietary technologies include rapid gene synthesis-independent TCR cloning and optimized aAPC models, enabling precise and effective therapeutic interventions for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors and viral diseases pose significant challenges due to their complex intracellular mechanisms, which are difficult to target with traditional therapies. Current treatment options often lack the precision needed to effectively eliminate diseased cells while sparing healthy tissue.
Solution
Lealing Biopharma develops T cell receptor (TCR)-based T cell therapies and TCR dual-antibody drugs designed to target intracellular mechanisms for the treatment of solid tumors and viral diseases. The company's approach leverages rapid gene synthesis-independent TCR cloning and optimized artificial antigen-presenting cell (aAPC) models to create precise and effective therapeutic interventions. These technologies enable the development of therapies that can specifically recognize and eliminate diseased cells, potentially improving patient outcomes.
Target Audience
The primary target audience includes patients with solid tumors and viral diseases who are seeking more effective and targeted treatment options.
Features
- Rapid gene synthesis-independent TCR cloning for efficient identification of therapeutic TCRs
- Optimized aAPC models for enhanced T cell activation and expansion
- Development of TCR-T cell therapies for solid tumors
- Development of TCR dual-antibody drugs for viral diseases